1 |
Beghe, B.; Rabe, K. F.; Fabbri, L. M. American Journal of Respiratory and Critical Care Medicine 2013, 188, 271.
DOI
|
2 |
Giembycz, Mark, A.; Stephen K. F. Drug Design, Development and Therapy 2010, 4,147.
|
3 |
Boland, S.; Alen, J.; Bourin, A.; Castermans, K.; Boumans, N.; Panitti, L.; Vanormelingen, J.; Leysen, D.; Defert, O. Bioorg. Med. Chem. Lett. 2014, http://dx.doi.org/10.1016/j.bmcl.2014.07.016
|
4 |
ICH, International Conference on Harmonization Guidance for Industry, Impurities in New Drug Products Q3B (R2). 2006.
|
5 |
ICH, Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization, IFPMA, Geneva. 2003.
|
6 |
ICH, Impurities in New Drug Substances Q3A (R2), International Conference on Harmonization, IFPMA, Geneva. 2006.
|
7 |
Tarek, S. B.; Hytham, M. A.; Mohamed, S. M.; Hoda, G. D.; Mostafa, M. B. Bulletin of Faculty of Pharmacy Cairo University 2014, 5279.
|
8 |
Barhate, V. D.; Deosthalee, P. Indian J. Pharm. Sci. 2010, 72, 401.
DOI
|
9 |
Sun, C.; Lin, Y.; Sun, M.; Wang, D.; Chen, L. Research on Chemical Intermediates 2013, 1.
|
10 |
Zhang, H.; Lin, Y.; Li, Y.; Dong, K.; Chen, L.; Wang, D. Journal of Chemical Research 2014, 38, 507.
DOI
|
11 |
Lin, Y.; Huang, P.; Qi, H.; Chen, L.; Wang, D. Research on Chemical Intermediates 2013,39, 3111.
DOI
|
12 |
Alex, A.; Harvey, S.; Parsons, T.; Pullen, F. S.; Wright, P.; Riley, J. A. Rapid Commun. Mass Spectrom. 2009, 23, 2619.
DOI
|
13 |
Wright, P.; Alex, A.; Nyaruwata1, T.; Parsons, T.; Pullen, F. Rapid Commun. Mass Spectrom. 2010, 24, 1025.
DOI
|
14 |
Wright, P.; Alex, A.; Pullen, F. S. Rapid Commun. Mass Spectrom. 2014, 28, 1127.
DOI
|